Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087986 | 0.98 | HSD17B3 (0.71) | HSD17B3HTTTHRANPC1RAB9A | |
| SCHEMBL6345972 | 0.86 | HSD17B3 (0.61) | HSD17B3HTTTHRAHDAC1HDAC8 | |
| SCHEMBL6341409 | 0.86 | HSD17B3 (0.61) | HSD17B3HTTTHRAHDAC1HDAC8 | |
| SCHEMBL12065064 | 0.85 | SMN1; SMN2 (0.67) | HSD17B3THRANPC1RAB9AHDAC1 | |
| SCHEMBL9805742 | 0.85 | HPGD (0.53) | HSD17B3NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL29879194 | 0.84 | SMN1; SMN2 (0.58) | HSD17B3NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL4953757 | 0.84 | HDAC1 (0.68) | HSD17B3THRANPC1RAB9AHDAC1 | |
| SCHEMBL12952426 | 0.84 | HDAC1 (0.68) | HSD17B3THRANPC1RAB9AHDAC1 | |
| SCHEMBL9805782 | 0.84 | HSD17B3 (0.49) | HSD17B3NPC1RAB9AHDAC1HDAC8 | |
| SCHEMBL1919198 | 0.83 | HSD17B3 (1.00) | HSD17B3HTTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049306-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2005-03-03 | — | — | US | claimed |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2002-08-15 | — | — | US | claimed |
| US-20050049306-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2005-03-03 | — | — | US | disclosed |
| US-6838583-B2 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and the methods of using the same | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1409443-A2 | NON-HALOGENATED NAPHTHOL COMPOUNDS, ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | WARNER-LAMBERT COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | disclosed |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | HARPER DAVID SCOTT (US) | 2002-08-15 | — | — | US | disclosed |
| WO-2002050001-A2 | NON-HALOGENATED NAPHTHOL COMPOUNDS AND ANTIMICROBIAL COMPOSITIONS CONTAINING THE SAME | WARNER-LAMBERT COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049306-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | HSD17B3 1904/4885HTT 1677/4885THRA 4061/4885 |
| US-20040010046-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | HSD17B3 1904/4885HTT 1677/4885THRA 4061/4885 |
| US-20020110530-A1 | Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same | NPM1, NOC2L, NAF1 | HSD17B3 1904/4885HTT 1677/4885THRA 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.